Geodon Competitors

INVEGA combines: The active metabolite of RISPERDAL® (risperidone) Innovative OROS® extended-release technology INVEGA demonstrated: Significant efficacy in the positive and negative symptoms of schizophrenia, Low weight gain and EPS rates comparable with placebo at the recommended 6-mg dose Total EPS-related adverse events at the 9-mg and 12-mg doses were 25, and 26,, respectively (versus 11, for placebo) The proportion of subjects having a weight gain of 7, body weight were comparable with placebo (5,) for 3 mg (7,) and 6 mg (6,). a higher incidence was seen for 9 mg (9,) and 12 mg (9,) Extensively studied in: 1665 patients with moderate to severe schizophrenia INVEGA,easy convenient dosing: Less than 10, of the dose is metabolized by any of the 4 identified metabolic pathways Not expected to cause clinically important interactions with drugs metabolized by the CYP450 pathway No dose adjustments for patients with mild to moderate hepatic impairment The short-term efficacy of INVEGA (3 to 15 mg once daily) was established in three placebo-controlled and active-controlled (olanzapine), 6-week, fixed-dose trials in non-elderly adult subjects (mean age of 37) who met DSM-IV criteria for schizophrenia: INVEGA delivered a full range of symptom control INVEGA offered an incidence of weight gain similar to that for placebo INVEGA delivered discontinuation rates due to adverse events that are similar to those for placebo across all doses Please see Product Details. Please see the full US Prescribing Information.

In addition to its specific indications for Bipolar I Disorder, ABILIFY is indicated for the treatment of schizophrenia including maintaining stability in adults who had been symptomatically stable on other antipsychotic medications for periods of three months or longer and observed for relapse during a period of up to 26 weeks. Physicians who elect to use ABILIFY for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual.

Zyprexa is indicated in the United States for the short- and long-term treatment of schizophrenia, acute mixed and manic episodes of bipolar I disorder, and maintenance treatment of bipolar disorder. Since Zyprexa was introduced in 1996, it has been prescribed to approximately 20 million people worldwide. Zyprexa is not approved for the treatment of patients with dementia- related psychosis. Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared with those patients taking a placebo. In addition, compared to elderly patients with dementia-related psychosis taking a placebo, there was a significantly higher incidence of cerebrovascular adverse events in elderly patients with dementia-related psychosis treated with Zyprexa. Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics, including Zyprexa. As with all antipsychotic medications, a rare and potentially fatal condition known as NMS has been reported with Zyprexa. If signs and symptoms appear, immediate discontinuation is recommended. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. Also, as with all antipsychotic treatment, prescribing should be consistent with the need to minimize Tardive Dyskinesia (TD). The risk of developing TD and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic increase. The syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. The most common treatment-emergent adverse event associated with Zyprexa in placebo-controlled, short-term schizophrenia and bipolar mania trials was somnolence. Other common events were dizziness, weight gain, personality disorder (COSTART term for nonaggressive objectionable behavior), constipation, akathisia, postural hypotension, dry mouth, asthenia, dyspepsia, increased appetite and tremor.